

Drug Treatment and Women's Health (EURAS/INAS)

First published: 14/09/2018

Last updated: 20/08/2024

Network

Network identification

PURI

<https://redirect.ema.europa.eu/resource/25544>

Network ID

25544

Network countries

- ☐ Austria
- ☐ Belgium
- ☐ Czechia
- ☐ Finland
- ☐ France
- ☐ Germany
- ☐ Hungary
- ☐ Italy
- ☐ Netherlands
- ☐ Poland

- ☐ Spain
 - ☐ Sweden
 - ☐ Switzerland
 - ☐ United Kingdom
-

Network website

<https://www.zeg-berlin.de>

ENCePP partner

No

Network description

Networks for prospective, controlled long-term cohort studies of women under normal-life-conditions (non-interventional observation) with active follow-up to get information about changes in health conditions (diseases, co-morbidities), currently with focus on possible adverse events of different hormonal drug treatments. Accrual of participants by networks of voluntary participating physicians. Established networks in many countries (Europe/North America/Australia), extensible on demand. Data about history of diseases and drug treatment and the development over time are usually collected in 6 months intervals from participating women (complex validation procedure) and physicians. The network started in the year 2000. A few studies with specific research questions on hormonal treatment finished already others are continuing. The number of countries in the networks is steadily increasing as are the women under surveillance.

Network details

Network primary therapeutic area:

- Cardiovascular diseases
 - Disorders of the central nervous system
 - Endocrine disorders
 - Gastrointestinal tract
 - Gynaecology
 - Liver disease
 - Malignant disease
 - Nutrition and blood
 - Osteoporosis
 - Pregnancy
 - Psychiatry
 - Renal impairment
 - Urinary tract disorders
-

Network funding:

- • Pharmaceutical company and other private sector

Contact

Klaas Heinemann

Main

k.heinemann@zeg-berlin.de

Christine Hagemann

Alternate

hagemann@zeg-berlin.de